Anti Vegf Eylea Hd denied for missing prior authorization by Humana?

Humana's specific coverage criteria for anti vegf eylea hd are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Requires Prior Authorization for Eylea HD

Humana requires prior authorization (PA) for Eylea HD (high-dose aflibercept) as a utilization-management tool. A denial framed as "prior authorization required" typically means either that no PA was submitted before the drug was administered or dispensed, or that a submitted PA was denied because the documentation did not satisfy Humana's coverage criteria. The second scenario is the more common one when patients are appealing, and it is fully contestable.

## Why This Denial Is Appealable

A PA denial is not a final coverage determination — it is a preliminary finding that the submitted clinical information was insufficient or did not meet Humana's stated criteria. Under ERISA §503 and ACA §2719, you have the right to a full internal review of that decision and, if necessary, an independent external review. Because Eylea HD is FDA-approved for specific retinal indications and supported by recognized retinal-disease guidelines, a well-documented appeal frequently succeeds.

## Federal Appeal Framework

• Internal appeal (ERISA §503 / ACA §2719): Submit within the timeframe on the denial letter (often 180 days for standard; shorter windows for ongoing treatment).
• External review: Available through an accredited IRO after final internal denial, generally within four months of that decision.
• Expedited review: For active retinal disease with risk of irreversible vision loss, request a 72-hour expedited PA review or expedited appeal in writing, with documented clinical urgency.
• Concurrent retroactive appeal: If the drug was already administered, file a retroactive PA appeal immediately and request that Humana waive the PA requirement given documented clinical urgency.

## Concrete Appeal Steps and Timeline

1. Obtain the PA denial letter and Humana's published prior-authorization criteria for aflibercept. 2. Identify each criterion listed in the PA policy and determine which was flagged as unmet. 3. Have the ophthalmologist update the PA submission or letter to address each unmet criterion specifically. 4. Submit the internal appeal package with imaging, chart notes, and the updated prescriber letter. 5. Request expedited review in writing with documentation of active disease. 6. If denied internally, file for external IRO review immediately.

## Documentation to Gather

• Diagnosis and imaging: Current OCT, fluorescein angiography, and visual-acuity measurements confirming the qualifying retinal condition.
• Treatment history: Documentation of any prior anti-VEGF or other retinal therapies, including dates, drug names, and clinical response.
• Clinical severity: Chart language quantifying lesion activity, fluid, and visual-acuity trajectory at the time of the PA request.
• Prescriber medical-necessity letter: Must address each PA criterion by name and provide chart-based evidence that the patient meets it.
• Humana PA criteria document: Obtain the current version so the appeal maps to the exact language Humana's reviewers will use.

## Criteria-Mapping Structure

Copy each PA criterion from Humana's published policy verbatim into a table. In the adjacent column, write the specific chart fact — date, finding, measurement, or clinical note — that satisfies that criterion. Attach the supporting records as labeled exhibits. This structure makes it straightforward for a medical reviewer to verify compliance with every requirement.